EPIS® Právní systém | Plné znění

XXXXXXXX KOMISE V PŘENESENÉ XXXXXXXXX (XX) 2022/692

xx xxx 16. února 2022,

xxxxxx xx pro xxxxx xxxxxxxxxxxx vědeckotechnickému xxxxxxx xxxx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 x&xxxx;xxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx

(Xxxx x&xxxx;xxxxxxxx xxx XXX)

XXXXXXXX XXXXXX,

x&xxxx;xxxxxxx xx Xxxxxxx x&xxxx;xxxxxxxxx Xxxxxxxx xxxx,

x&xxxx;xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 ze xxx 16.&xxxx;xxxxxxxx&xxxx;2008 x&xxxx;xxxxxxxxxxx, označování x&xxxx;xxxxxx xxxxx a směsí, x&xxxx;xxxxx x&xxxx;xxxxxxx xxxxxxx 67/548/XXX x&xxxx;1999/45/XX a o změně xxxxxxxx (XX) x.&xxxx;1907/2006&xxxx;(1), x&xxxx;xxxxxxx na xx.&xxxx;37 xxxx.&xxxx;5 xxxxxxxxx xxxxxxxx,

xxxxxxxx x&xxxx;xxxxx důvodům:

(1)	Tabulka 3 x&xxxx;xxxxx 3 přílohy XX xxxxxxxx (XX) x.&xxxx;1272/2008 xxxxxxxx seznam xxxxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxxxxx xxxxx na xxxxxxx xxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxx 2 xx 5 xxxxxxx X&xxxx;xxxxxxxxx xxxxxxxx.

(2)

Xxxxxxxx xxxxxxxx pro xxxxxxxx látky (dále xxx „xxxxxxxx“) xxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxx&xxxx;37 nařízení (XX) č. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxx xxxxx x&xxxx;xx xxxxxxxxxxx nebo xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxx xxxxxxxxx jiných xxxxx. Xxxx, xx Výbor xxx xxxxxxxxxx xxxxx (XXX) agentury xxxxxxxxx xxxxxxxxxx zúčastněných xxxxx, xxxxxx x&xxxx;xxxxx návrhům xxxxxxxxxxx stanoviska (2):

—	stanovisko ze xxx 5. prosince 2019 xxx xxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, produkty xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx křemičitý v nanoformě x&xxxx;xxxxxxxxxx xxxxxxx,

—	xxxxxxxxxx xx xxx 4. května 2020 pro xxxxxxxxxx (XXX), [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—

xxxxxxxxxx xx xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx β-xxxxxxxxxx (XXX); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx- (1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx,

—	xxxxxxxxxx xx xxx 4.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (ISO); (1E)-N-[(6-chlorpyridin-3-yl)methyl]-N’-kyan-N-methylethanimidamid; (X)-X 1-[(6-xxxxx-3-xxxxxxx)xxxxxx]-X 2-kyan-N 1-xxxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx tellur,

—	stanovisko xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx oxid xxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxxx 2,2-xxxxxxxxxxxxxx-1-xxx; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx,

—	xxxxxxxxxx ze dne 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxxxxxxx (XXX); 5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6-xxxxxx-1,3-xxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 11. června 2020 xxx xxxxxxxxxx,

—	xxxxxxxxxx xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxx xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx,

—	xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxx (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxxx kyselinu; X-(xxxxxxxxxxxxx)xxxxxxxxxxxx kyselinu,

—	stanovisko ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); 3,6-bis(o-chlorfenyl)-1,2,4,5-tetrazin,

—	stanovisko xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx xxxxxxxxxxx (XXX); 2,6-xxxxxxx-X-[3-xxxxx-5-(xxxxxxxxxxxxxx)-2-xxxxxxx]xxxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 pro xxxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx soli,

—	stanovisko xx xxx 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxx {[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx kyseliny x&xxxx;xxxxxx xxxxxxxxxxxx a pentadraselných xxxx xx xxxxxx Xxxxxxxx komise,

—	stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 pro xxxxxxxxxx-xxx(2-xxxxxxxxxxxxx),

—	xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxxx-xxxxxxxx,

—	xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx xxxxxxxxx xxxxxxx-xxxxxxxx,

—	xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx chinoklamin (XXX); 2-xxxxx-3-xxxxx-1,4-xxxxxxxxxxx,

—	xxxxxxxxxx ze dne 17.&xxxx;xxxx&xxxx;2020 pro 4,4’-xxxxx(xxxxxxxxxxxxxxxxxxxxx),

—	xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx toluen-4-sulfonohydrazid,

—	stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 pro xxxxxxxxx; 1,3-dimethyl-3,7-dihydro-1H-purin-2,6-dion,

—	stanovisko xx xxx 17.&xxxx;xxxx&xxxx;2020 pro 1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [m-TMXDI],

—	stanovisko ze xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,3-xxx(xxxxxxxxxxxxxxxx)xxxxxx; [x-XXX],

—	xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx,

—	xxxxxxxxxx ze dne 17.&xxxx;xxxx&xxxx;2020 pro xxxxxxx xxxxxxxx X-(2-xxxxxxxxxx)xxxxxxxxxx,

—	xxxxxxxxxx ze xxx 17.&xxxx;xxxx&xxxx;2020 pro xxxxx,

—	xxxxxxxxxx xx dne 17.&xxxx;xxxx&xxxx;2020 xxx 2-xxxxx-2-{[(1-xxxxxxxx)xxx]xxxxxx}xxxxxx-1,3-xxxx-xxxxxxxxx; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx; xxxxxxxxxxxxxxxxx-xxxxxxxxxx,

—	xxxxxxxxxx xx xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,5-xxxxxxxxxxxxxxxxxxxx [xxxxxxxxxx < 0,1 % xxxx. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxxxxx xxx 50 μm],

—	stanovisko ze xxx 17.&xxxx;xxxx&xxxx;2020 xxx 1,5-xxxxxxxxxxxxxxxxxxxx [obsahující ≥ 0,1 % xxxx. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx menším než 50 μx],

—	xxxxxxxxxx xx xxx 8. října 2020 xxx xxxxxx xxxxxx,

—	xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 pro 2,4,6-xxx-xxxx-xxxxxxxxxx,

—	xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxxxx (XXX); 2,6-dichlor-4-(3,3-dichlorallyloxy)fenyl{3-[5-(trifluormethyl)-2-pyridyloxy]propyl}ether,

—	stanovisko xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxx-2-xxxxx-1-xxxx, sodnou xxx; xxxxxx xxx xxxxxxxxxx; xxxxxxxxx xxxxx,

—	xxxxxxxxxx ze xxx 8.&xxxx;xxxxx&xxxx;2020 xxx X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx,

—	xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx 2-(2-xxxxxxxxxxxxx)xxxxxxx; diethylenglykolmonomethylether,

—	stanovisko xx xxx 8. října 2020 xxx 4,4′-xxxxxxxxxxxxxxxxxxxx; bisfenol X,

—	xxxxxxxxxx xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxxxxxxxxx (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx,

—	xxxxxxxxxx xx dne 8.&xxxx;xxxxx&xxxx;2020 xxx dimoxystrobin (XXX); (2X)-2-{2-[(2,5-xxxxxxxxxxxxxx)xxxxxx]xxxxx}-2-(xxxxxxxxxxxx)-X-xxxxxxxxxxxxxx; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamid,

—	stanovisko xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 4,4’-xxxxxxxxxxxxxxx; xxxxxxxx X,

—	xxxxxxxxxx ze xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Xxxxxxxx Xxxx 124,

—	xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro kyselinu xxxxxxxxxxxxxxxxxx; xxxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—	xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxx-X-(xxxxxxxxxxxxxxxxxx)-X-xxxxx-(3XX)-3-(4-xxxxxxxxxx)-β-xxxxxxxx; xxxxxxxxxxx,

—	xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 6-[xxxxx-(X12-X18, rozvětvené, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx xxxxxxxx, sodné x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx soli,

—	stanovisko xx xxx 10. prosince 2020 pro 6-[xxxxx-(X10-X13, rozvětvené, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxxx xxxxxxxx,

—	xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 pro 6-[xxxxx-(X12-X18, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanovou xxxxxxxx,

—	xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx 1,3,5-xxxxxxx-2,4,6-xxxxxxx; xxxxxxx,

—

xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxx xxxx: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx x&xxxx;3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx [relativní xxxxx ≥&xxxx;78&xxxx;% xxx-xxxxxxx x&xxxx;≤&xxxx;15&xxxx;% xxxx-xxxxxxx], xxxxxxxxxx,

—	xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxx, extraktu [x&xxxx;xxxxx xxxxxxxx Azadirachta xxxxxx, xxxxxxxxxxx xxxxx x&xxxx;xxxx xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx],

—	xxxxxxxxxx xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx oxid xxxxxxxxx,

—	xxxxxxxxxx xx dne 10.&xxxx;xxxxxxxx&xxxx;2020 pro bentazon (XXX), 3-isopropyl-2,1,3-benzothiadiazin-4-on-2,2-dioxid,

—	stanovisko xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx nových xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxx xxxxxxxx 2-xxxxxxxxxxx-1-xxx; ethylenglykol-monobutyl-etheru (XXXX) xx xxxxxx Xxxxxxxx xxxxxx.

(3)

Xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx, xxxxx xxxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx ve xxxxxxxxxxxx XXX ze xxx 11.&xxxx;xxxxxx&xxxx;2020 xxx 2-xxxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx soli; xx dne 11.&xxxx;xxxxxx&xxxx;2020 xxxxxxx opětovného xxxxxxxxx xxxxxxxx xxxxxxxx {[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx x&xxxx;xxxxxx xxxxxxxxxxxx x&xxxx;xxxxxxxxxxxxxxx solí xx xxxxxx Xxxxxxxx xxxxxx, xx xxx 8.&xxxx;xxxxx&xxxx;2020 xxx xxxxxx amonný, xx xxx 10. prosince 2020 xxx xxxx xxxxxxxxx, xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxx xxxxxxxxx o akutní xxxxxxxxx xxxxxxxx 2-xxxxxxxxxxx-1-xxx; xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx (XXXX) xx xxxxxx Xxxxxxxx xxxxxx x&xxxx;xx xxx 10.&xxxx;xxxxxxxx&xxxx;2020 xxx xxxxxxx.

(4)

Xxxxxx tyto xxxxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx xx xx xxxxxxxxxx x&xxxx;xxxx, xxx xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxxxx ve stanoviscích XXX. Na základě xxxxxxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxx xx proto xxxxxx zavést, xxxxxxxxxxxx xxxx xxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx a označení xxxxxxxxx xxxxx.

(5)

Xxxx, xx bylo Xxxxxx xxxxxxx stanovisko XXX, xxxx xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxx xx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxx, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx hydrolýzy x&xxxx;xxxxxx xxxxxxxxxx; xxxxxxxxxxx syntetického xxxxxxxxx xxxxx xxxxxxxxxxx x&xxxx;xxxxxxxxx s povrchovou xxxxxxx. Xxxxxxxxxxx silanaminu, 1,1,1-xxxxxxxxx-X-(xxxxxxxxxxxxxx)-, xxxxxxxx xxxxxxxxx x&xxxx;xxxxxx xxxxxxxxxx; pyrogenního syntetického xxxxxxxxx oxidu xxxxxxxxxxx x&xxxx;xxxxxxxxx s povrchovou xxxxxxx xxxx xxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxx 2, xxxxxxxxxx xx stanovisku XXX xx xxx 5.&xxxx;xxxxxxxx&xxxx;2019, xx neměla xxx zařazena do xxxxxxx XX xxxxxxxx (XX) č. 1272/2008, neboť Xxxxxx xxxx xxxxxxx xxxxxxxxx xxxxxxxxx x&xxxx;xxxxxxxxxx, xx xx bylo xxxxx xxxxx xxxxxxxxx XXX. Xx xxxxxxx XX nařízení (XX) x.&xxxx;1272/2008 by xxxx xxxx xxx xxxxxxxx xxxxxxxxxxx této xxxxx xxxx XXXX RE 2, doporučená xx xxxxxxxxxx xxxxxx XXX xx xxx 5. prosince 2019, xxxxx xxxxxx xxxxxxxx xxxxx nové xxxxxxxxx, xxxxx xx xxxxxxxxxx xxxxx xxxxxxxxx xxxx xxxxxxxxxxx.

(6)	Xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxxx xxxx xxx odpovídajícím způsobem xxxxxxx.

(7)

Xxxxxxxxxx nových xxxx xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxx být xxxxxxxxxx xxxxx, jelikož xxxxxxxxxx potřebují určitou xxxx na xx, xxx přizpůsobili označování x&xxxx;xxxxxx látek a směsí xxxxx xxxx xxxxxxxxxxxxxx xxxxxxxxxxxx a prodali stávající xxxxxx, xx xxxxx xx xxxxxxxx xxxxxxxxx xxxxxxxxxxx xxxxxxxxx. Xxxx xxxx je xxxxxx xxxxxxxx x&xxxx;xxxx, xxx xxxxxxxxxx xxxx xxxxxxxx xxxx přijmout xxxxxxxx xxxxx x&xxxx;xxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxx xxxxxxxxx, xxxxx xxxxxxxx x&xxxx;xxxxxxxx xxxx provedených xxxxx xxxxxx nařízení. Xxxxxxxxxxx xx xxxx xxxx xxx xxxxxxxx xxxxxxxx nové nebo xxxxxxxxxxxxx harmonizované xxxxxxxxxxx x&xxxx;xxxxxxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxxxx x&xxxx;xxxxxx xx xxxxxxxxxxx xxxxxxx xxxx xxxxx xxxxxxxxxxxxx xxxxxx xxxxxxxx, aby byla xxxxxxxxx xxxxxx xxxxxx xxxxxxx xxxxxxxx zdraví x&xxxx;xxxxxxxxx prostředí x&xxxx;xxx xx dodavatelům xxxxxxxx xxxxxxxxxx xxxxxxxx,

XXXXXXX TOTO XXXXXXXX:

Xxxxxx&xxxx;1

Xxxxx nařízení (XX) x.&xxxx;1272/2008

Xxxxxxx XX nařízení (XX) č. 1272/2008 se xxxx x&xxxx;xxxxxxx x&xxxx;xxxxxxxx xxxxxx xxxxxxxx.

Xxxxxx&xxxx;2

Xxxxx x&xxxx;xxxxxxxx x&xxxx;xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje v platnost xxxxxxxx dnem xx xxxxxxxxx x&xxxx;Xxxxxxx xxxxxxxx Xxxxxxxx unie.

Použije xx xxx dne 23.&xxxx;xxxxxxxxx 2023.

Xxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xxxxxx xxxxx být xxxxx x&xxxx;xxxxx xxxxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx x&xxxx;xxxxxxx s tímto xxxxxxxxx xxx xxx xxxx vstupu x&xxxx;xxxxxxxx.

Xxxx nařízení xx xxxxxxx v celém xxxxxxx x&xxxx;xxxxx použitelné ve xxxxx xxxxxxxxx xxxxxxx.

X&xxxx;Xxxxxxx xxx 16. února 2022.

Xx Xxxxxx

xxxxxxxxxxx

Xxxxxx VON XXX XXXXX

(1)&xxxx;&xxxx;Xx. xxxx. X&xxxx;353, 31.12.2008, s. 1.

(2) Stanoviska jsou xxxxxxxx na xxxx xxxxxxxxxxx stránce: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/. – Xxxxxxxxxx ze xxx 11. června 2020 a ze xxx 10. prosince 2020 xxxxxxxx xx xxxxxxxxxx xxxxxxxxx xx xxxxxx Evropské xxxxxx xxxx k dispozici xx xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxx-xx/xxx-xx-xxx/xxxxxxxxx-xxx-xxxx-xxxxxxxxxx/xxxxxxxx-xx-xxx-xxx-xxxxxxx-xxxxx-xxxxxxxx-xxxx-x-xxxxxxxxx-xxxxxxxx-xxxxxxxx

PŘÍLOHA

Příloha XX xxxxxxxx (XX) x.&xxxx;1272/2008 xx xxxx xxxxx:

x&xxxx;xxxxx 3 xx xxxxxxx 3 xxxx xxxxx:

xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx	Xxxxxxxx xxxxx	Xxxxx XX	Xxxxx XXX	Xxxxxxxxxxx		Xxxxxxxx			Xxxxxxxxxx xxxxxxx. xxxxxx, xxxxxxxxxxxxx xxxxxxx x&xxxx;XXX	Xxxxxxxx
Xxxxxxxx xxxxx	Xxxxxxxx xxxxx	Xxxxx XX	Xxxxx XXX	Xxxx xxxx x&xxxx;xxxxxxxxx xxxxxxxxxxxxx	Xxxx standardních xxx x&xxxx;xxxxxxxxxxxxx	Xxxx xxxxxxxxxxx xxxxxxx a signálních slov	Kódy xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx	Xxxx xxxxx. standardních vět x&xxxx;xxxxxxxxxxxxx		Xxxxxxxx
„014-052-00-7	xxxxxxxxx, 1,1,1-trimethyl-N-(trimethylsilyl)-, xxxxxxxx xxxxxxxxx s oxidem křemičitým; xxxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxxxxx x&xxxx;xxxxxxxxx x&xxxx;xxxxxxxxxx xxxxxxx	272-697-1	68909-20-6	XXXX RE 2	X373 (xxxxx) (vdechování)	GHS08 Wng	H373 (xxxxx) (xxxxxxxxxx)	XXX066“
„035-005-00-7	xxxxxx amonný	235-183-8	12124-97-9	Repr. 1X Xxxx. XXXX XX 3 STOT XX 1 Eye Xxxxx. 2	X360XX X362 X336 X372 (nervový xxxxxx) X319	XXX08 XXX07 Xxx	X360XX X362 X336 X372 (xxxxxxx systém) H319“
„050-032-00-4	dibutylcín-bis(2-ethylhexanoát)	220-481-2	2781-10-4	Muta. 2 Xxxx. 1X XXXX XX 1	H341 H360FD H372 (xxxxxxxx xxxxxx)	XXX08 Xxx	X341 X360XX X372 (imunitní xxxxxx)“
„050-033-00-X	xxxxxxxxxx-xxxxxxxx	213-928-8	1067-33-0	Xxxx. 2 Xxxx. 1X XXXX XX 1	X341 X360XX X372 (xxxxxxxx xxxxxx)	XXX08 Xxx	X341 X360XX X372 (imunitní xxxxxx)“
„052-001-00-0	xxxxxx	236-813-4	13494-80-9	Xxxx. 1X Xxxx.	X360Xx X362	XXX08 Xxx	X360Xx X362“
„052-002-00-6	xxxx xxxxxxxxxxx	231-193-1	7446-07-3	Xxxx. 1B Lact.	H360Df H362	GHS08 Dgr	H360Df H362“
„056-005-00-3	tetraoxid xxxxxxx-xxxxxxxx	237-222-4	13701-59-2	Xxxx. 1X Xxxxx Xxx. 4 Xxxxx Xxx. 3	H360FD H332 H301	GHS08 GHS06 Dgr	H360FD H332 H301		inhalační: ATE = 1,5&xxxx;xx/x (xxxxx nebo xxxx) xxxxxx: XXX&xxxx;= 100 mg/kg TH“
„601-097-00-8	propylbenzen	203-132-9	103-65-1	Flam. Xxx. 3 Xxx. Xxx. 1 XXXX XX 3 Xxxxxxx Xxxxxxx 2	X226 X304 X335 X411	XXX02 XXX08 XXX07 XXX09 Xxx	X226 X304 X335 X411“
„603-243-00-6	xxxxxxxxxxxxxx 2,2-dimethylpropan-1-olu; 3-xxxx-2,2-xxx(xxxxxxxxxx)xxxxxx-1-xx	253-057-0	36483-57-5; 1522-92-5	Carc. 1X Xxxx. 2	X350 X341	XXX08 Xxx	X350 X341“
„604-096-00-0	xxxxxxxxxxxxxxxx (ISO); 5-{[2-(2-xxxxxxxxxxxx)xxxxxx]xxxxxx}-6-xxxxxx-1,3-xxxxxxxxxxx	200-076-7	51-03-6	XXXX XX 3 Eye Xxxxx. 2 Xxxxxxx Acute 1 Aquatic Xxxxxxx 1	X335 X319 X400 X410	XXX07 XXX09 Xxx	X335 X319 X410	XXX066	X&xxxx;= 1 X&xxxx;= 1“
„604-097-00-6	2,4,6-xxx-xxxx-xxxxxxxxxx	211-989-5	732-26-3	Xxxx. 1X Xxxxx Tox. 4 XXXX XX 2 Skin Xxxx. 1X	X360X X302 X373 (xxxxx) X317	XXX08 XXX07 Xxx	X360X X302 X373 (xxxxx) X317		xxxxxx: XXX&xxxx;= 500&xxxx;xx/xx XX“
„604-098-00-1	4,4’-xxxxxxxxxxxxxxx; xxxxxxxx X	201-250-5	80-09-1	Xxxx. 1B	H360FD	GHS08 Dgr	H360FD“
„606-153-00-5	benzofenon	204-337-6	119-61-9	Carc. 1X	X350	XXX08 Xxx	X350“
„606-154-00-0	xxxxxxxxxxx (ISO); 2-amino-3-chlor-1,4-naftochinon	220-529-2	2797-51-5	Carc. 2 Xxxx. 2 Xxxxx Tox. 4 XXXX XX 2 Eye Xxxxx. 2 Xxxx Xxxx. 1&xxxx;X Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	H351 H361d H302 H373 (xxxxxx xxxx, xxxxxxx) X319 X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X351 X361x X302 X373 (xxxxxx xxxx, ledviny) H319 H317 H410		orální: ATE = 500 mg/kg XX X&xxxx;= 10 X&xxxx;= 10“
„607-756-00-6	xxx-1,7,7-xxxxxxxxxxxxxxxx[2.2.1]xxxx-2-xx-xxxxxxx; xxxxxxxxx-xxxxxxx	227-561-6	5888-33-5	Xxxx Sens. 1&xxxx;X	X317	XXX07 Xxx	X317“
„607-757-00-1	xxxxxxxxx (XXX); 4-(2,2-xxxxxxxxxxxxxxxxx)-4-xxxxxxxxxxx xxxxxxxx; X-(xxxxxxxxxxxxx)xxxxxxxxxxx xxxxxxxx	216-485-9	1596-84-5	Xxxx. 2	X351	XXX08 Xxx	X351“
„607-758-00-7	4,4′-xxxxx(xxxxxxxxxxxxxxxxxxxxx)	201-286-1	80-51-3	Xxxx-xxxxx. X Xxxxxxx Acute 1 Aquatic Xxxxxxx 1	X242 X400 X410	XXX02 XXX09 Xxx	X242 X410		X&xxxx;= 1 X&xxxx;= 1“
„607-759-00-2	xxxxxx-4-xxxxxxxxxxxxxxx	216-407-3	1576-35-8	Xxxx-xxxxx. X	X242	XXX02 Xxx	X242“
„607-760-00-8	2-{X-xxxxx-4-[(5-xxxxxxxxxxxx-2-xx)xxx]-x-xxxxxxxxx}xxxxx-xxxxxx; X.X. Xxxxxxxx Xxxx 124	239-203-6	15141-18-1	Xxxx Xxxx. 1&xxxx;X	X317	XXX07 Xxx	X317		Xxxx Xxxx. 1&xxxx;X; X317: C ≥ 0,001 %“
„607-761-00-3	perfluorheptanová xxxxxxxx; tridekafluorheptanová xxxxxxxx	206-798-9	375-85-9	Xxxx. 1X XXXX RE 1	X360X X372 (xxxxx)	XXX08 Xxx	X360X X372 (xxxxx)“
„607-762-00-9	xxxxxx-X-(xxxxxxxxxxxxxxxxxx)-X-xxxxx-(3XX)-3-(4-xxxxxxxxxx)-β-xxxxxxxx; xxxxxxxxxxx	-	283159-90-0	Xxxx. 2 Xxxxxxx Chronic 2	X351 X411	XXX08 XXX09 Xxx	X351 X411“
„607-763-00-4	6-[xxxxx-(X12-X18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx xxxxxxxx, xxxxx x&xxxx;xxxx(2-xxxxxxxxxxxx)xxxxxx soli	-	-	Repr. 1X Xxx Xxxxx. 2	X360XX X319	XXX08 XXX07 Xxx	X360XX X319“
„607-764-00-X	6-[xxxxx-(X10-X13, xxxxxxxxxx, nenasycené)-2,5-dioxopyrrolidin-1-yl]hexanová xxxxxxxx	-	2156592-54-8	Xxxx. 1X Xxx Xxxxx. 2	H360FD H319	GHS08 GHS07 Dgr	H360FD H319“
„607-765-00-5	6-[alkyl-(C12-C18, xxxxxxxxxx, xxxxxxxxxx)-2,5-xxxxxxxxxxxxxxx-1-xx]xxxxxxxx xxxxxxxx	-	-	Xxxx. 1X	X360XX	XXX08 Xxx	X360XX“
„613-341-00-0	xxxxxxxxxxx (XXX); 3,6-xxx(x-xxxxxxxxxx)-1,2,4,5-xxxxxxxx	277-728-2	74115-24-5	Xxxxxxx Xxxxxxx 1	H410	GHS09 Wng	H410		M = 1“
„613-342-00-6	xxxxxxxxx; 1,3-xxxxxxxx-3,7-xxxxxxx-1X-xxxxx-2,6-xxxx	200-385-7	58-55-9	Xxxx. 1X	X360X	XXX08 Xxx	X360X“
„613-343-00-1	xxxxxxxxx (XXX); 2,6-xxxxxxx-4-(3,3-xxxxxxxxxxxxxxx)xxxxx{3-[5-(xxxxxxxxxxxxxx)-2-xxxxxxxxxx]xxxxxx}xxxxx	-	179101-81-6	Xxxx Xxxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	X317 X400 X410	XXX07 XXX09 Xxx	X317 X410		X&xxxx;= 1&xxxx;000 X&xxxx;= 100“
„613-344-00-7	xxxxxxx-2-xxxxx-1-xxxx, xxxxx xxx; xxxxx xxx xxxxxxxxxx; pyrithion xxxxx	223-296-5; 240-062-8	3811-73-2; 15922-78-8	Xxxxx Xxx. 3 Xxxxx Xxx. 3 Xxxxx Tox. 4 XXXX RE 1 Xxxx Xxxxx. 2 Eye Xxxxx. 2 Xxxx Sens. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 2	X331 X311 X302 X372 (nervový systém) H315 H319 H317 H400 H411	GHS06 GHS08 GHS09 Dgr	H331 H311 H302 H372 (xxxxxxx systém) H315 H319 H317 H410	EUH070	inhalační: ATE = 0,5&xxxx;xx/x (xxxxx xxxx mlha) dermální: ATE = 790&xxxx;xx/xx XX xxxxxx: XXX&xxxx;= 500&xxxx;xx/xx XX X&xxxx;= 100“
„613-345-00-2	1,3,5-triazin-2,4,6-triamin; melamin	203-615-4	108-78-1	Carc. 2 XXXX XX 2	X351 X373 (xxxxxx xxxxx)	XXX08 Xxx	X351 X373 (xxxxxx xxxxx)“
„615-046-00-2	1,3-xxx(1-xxxxxxxxxx-1-xxxxxxxxxxx)xxxxxx; [x-XXXXX]	220-474-4	2778-42-9	Xxxx. Sens. 1 Skin Xxxx. 1 A	H334 H317	GHS08 Dgr	H334 H317“
„615-047-00-8	1,3-bis(isokyanatomethyl)benzen; [x-XXX]	222-852-4	3634-83-1	Xxxx. Xxxx. 1 Xxxx Xxxx. 1&xxxx;X	X334 X317	XXX08 Xxx	X334 X317		Xxxx Xxxx. 1&xxxx;X; X317: X&xxxx;≥&xxxx;0,001&xxxx;%“
„615-048-00-3	2,4,6-xxxxxxxxxxxx-x-xxxxxxx-xxxxxxxxxxx	218-485-4	2162-73-4	Xxxx. Xxxx. 1 Xxxx Sens. 1	H334 H317	GHS08 Dgr	H334 H317“
„615-049-00-9	1,5-diisokyanatonaftalen [obsahující &xx;&xxxx;0,1&xxxx;% xxxx. xxxxxx x&xxxx;xxxxxxxxxxxxxx xxxxxxxx xxxxxx xxx 50 μx]	221-641-4	3173-72-6	XXXX XX 3 Xxxx Xxxxx. 2 Xxx Xxxxx. 2 Resp. Xxxx. 1 Xxxx Sens. 1&xxxx;X Xxxxxxx Chronic 3	X335 X315 X319 X334 X317 X412	XXX07 XXX08 Xxx	X335 X315 X319 X334 X317 X412“
„615-050-00-4	1,5-xxxxxxxxxxxxxxxxxxxx [xxxxxxxxxx &xx;&xxxx;0,1&xxxx;% hmot. částic x&xxxx;xxxxxxxxxxxxxx průměrem xxxxxx xxx 50 μm]	221-641-4	3173-72-6	Acute Xxx. 2 XXXX XX 3 Xxxx Irrit. 2 Xxx Xxxxx. 2 Resp. Xxxx. 1 Xxxx Sens. 1 A Aquatic Xxxxxxx 3	X330 X335 X315 X319 X334 X317 X412	XXX06 XXX08 Xxx	X330 X335 X315 X319 X334 X317 X412		xxxxxxxxx: XXX&xxxx;= 0,27 mg/l (xxxxx nebo xxxx)“
„616-237-00-3	xxxxxxxxxxx (XXX); 2,6-dichlor-N-[3-chlor-5-(trifluormethyl)-2-pyridyl]methylbenzamid	-	239110-15-7	Repr. 2	X361x	XXX08 Xxx	X361x“
„616-238-00-9	xxxxxxx xxxxxxxx X-(2-xxxxxxxxxx)xxxxxxxxxx	477-690-9	874819-71-3	Xxxx. 1X XXXX XX 2	X360Xx X373 (xxxxxxx)	XXX08 Xxx	X360Xx X373 (xxxxxxx)“
„616-239-00-4	X-(5-xxxxx-2-xxxxxxxxxxxxxxx)-X-xxxxxxxxxxx-3-(xxxxxxxxxxxxx)-5-xxxxx-1-xxxxxx-1X-xxxxxxx-4-xxxxxxxxxx; xxxxxxxxxxxx	-	1255734-28-1	Xxxx. 2 Acute Xxx. 4 Skin Sens. 1X Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1	X361x X332 X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X361x X332 X317 X410		xxxxxxxxx: XXX&xxxx;= 2,2&xxxx;xx/x (xxxxx xxxx xxxx) X&xxxx;= 10 X&xxxx;= 1“
„616-240-00-X	xxxxxxx směs: 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-[(1XX,4XX,9XX)-1,2,3,4-xxxxxxxxxx-9-xxxxxxxxx-1,4-xxxxxxxxxxxxxxx-5-xx]xxxxxxx-4-xxxxxxxxxx a 3-(difluormethyl)-1-methyl-N-[(1RS,4SR,9SR)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaftalen-5-yl]pyrazol-4-karboxamid [xxxxxxxxx xxxxx ≥&xxxx;78&xxxx;% xxx-xxxxxxx x&xxxx;≤&xxxx;15&xxxx;% xxxx-xxxxxxx], xxxxxxxxxx	-	881685-58-1	Xxxx. 2 Xxxx. 1X Xxxx Sens. 1X Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1	X351 X360X X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X351 X360X X317 X410		Xxxx. 1X; X360X: X&xxxx;≥&xxxx;3&xxxx;% X&xxxx;= 10 X&xxxx;= 10“
„650-058-00-1	Xxxxxxx, xxxxxxx [x&xxxx;xxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx, xxxxxxxxxxx xxxxx a dále xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx]	283-644-7	84696-25-3	Xxxx. 2 Xxxx Sens. 1 Xxxxxxx Xxxxxxx 1	X361x X317 X410	XXX08 XXX07 XXX09 Xxx	X361x X317 X410		X&xxxx;= 10“

xxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxxx 014-001-00-9; 023-001-00-8; 601-024-00-X; 603-014-00-0; 603-107-00-6; 604-030-00-0; 607-111-00-9; 607-230-00-6; 607-253-00-1; 607-254-00-7; 607-734-00-6; 607-735-00-1; 607-736-00-7; 608-032-00-2; 609-042-00-X; 613-012-00-1; 616-164-00-7 xx xxxxxxxxx těmito xxxxxxxxx:

Xxxxxxxx xxxxx	Xxxxxxxx xxxxx	Xxxxx ES	Číslo XXX	Xxxxxxxxxxx		Xxxxxxxx			Xxxxxxxxxx koncent. xxxxxx, xxxxxxxxxxxxx xxxxxxx x&xxxx;XXX	Xxxxxxxx
Xxxxxxxx xxxxx	Xxxxxxxx xxxxx	Xxxxx ES	Číslo XXX	Xxxx xxxx a kategorií nebezpečnosti	Kódy xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx	Xxxx xxxxxxxxxxx symbolů x&xxxx;xxxxxxxxxx xxxx	Xxxx standardních xxx x&xxxx;xxxxxxxxxxxxx	Xxxx doplň. xxxxxxxxxxxx xxx x&xxxx;xxxxxxxxxxxxx		Xxxxxxxx
„014-001-00-9	xxxxxxxxxxxxx	233-042-5	10025-78-2	Xxxx. Liq. 1 Xxxxx-xxxxx. 1 Acute Tox. 3 Xxxxx Tox. 4 Xxxx Xxxx. 1 A Eye Xxx. 1	X224 X260 X331 X302 X314 X318	XXX02 XXX06 XXX05 Xxx	X224 X260 X331 X302 X314	XXX014 XXX029 XXX071	xxxxxxxxx: XXX&xxxx;= 7,6&xxxx;xx/x (xxxx) xxxxxx: XXX&xxxx;= 1&xxxx;000 mg/kg XX“
„023-001-00-8	xxxx xxxxxxxxx	215-239-8	1314-62-1	Xxxx. 2 Xxxx. 1X Xxxx. 2 Xxxx. Xxxxx Xxx. 3 Xxxxx Xxx. 2 XXXX SE 3 XXXX XX 1 Xxxxxxx Xxxxxxx 2	X341 X350 X361xx X362 X301 X330 X335 X372 (dýchací xxxxx, xxxxxxxxxx) X411	XXX06 XXX08 XXX09 Xxx	X341 X350 X361xx X362 X301 X330 X335 X372 (dýchací xxxxx, vdechování) H411		inhalační: ATE = 0,05&xxxx;xx/x (xxxxx nebo xxxx) xxxxxx: XXX&xxxx;= 220&xxxx;xx/xx XX“
„601-024-00-X	xxxxx	202-704-5	98-82-8	Xxxx. Liq. 3 Xxxx. 1B Asp. Xxx. 1 XXXX XX 3 Xxxxxxx Xxxxxxx 2	H226 H350 H304 H335 H411	GHS02 GHS08 GHS07 GHS09 Dgr	H226 H350 H304 H335 H411“
„603-014-00-0	2-butoxyethan-1-ol; xxxxxxxxxxxxx-xxxxxxxxx-xxxxx	203-905-0	111-76-2	Xxxxx Xxx. 3 Xxxxx Tox. 4 Xxxx Xxxxx. 2 Xxx Xxxxx. 2	H331 H302 H315 H319	GHS06 Dgr	H331 H302 H315 H319		inhalační: ATE = 3&xxxx;xx/x (xxxx) xxxxxx: XXX&xxxx;= 1 200 &xxxx;xx/xx XX“
„603-107-00-6	2-(2-xxxxxxxxxxxxx)xxxxxxx; xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	203-906-6	111-77-3	Xxxx. 1X	X360X	XXX08 Xxx	X360X		Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;%“
„604-030-00-0	4,4′-xxxxxxxxxxxxxxxxxxxx; xxxxxxxx A	201-245-8	80-05-7	Repr. 1X XXXX XX 3 Xxx Dam. 1 Xxxx Xxxx. 1 Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1	X360X X335 X318 X317 X400 X410	XXX08 XXX07 XXX05 XXX09 Xxx	X360X X335 X318 X317 X410		X&xxxx;= 1 X&xxxx;= 10“
„607-111-00-9	2-xxxxx-2-{[(1-xxxxxxxx)xxx]xxxxxx}xxxxxx-1,3-xxxx-xxxxxxxxx; 2,2-xxx(xxxxxxxxxxxxxxxxx)xxxxx-xxxxxxx; xxxxxxxxxxxxxxxxx-xxxxxxxxxx	239-701-3	15625-89-5	Xxxx. 2 Xxxx Xxxxx. 2 Xxx Xxxxx. 2 Xxxx Xxxx. 1 Aquatic Xxxxx 1 Xxxxxxx Chronic 1	X351 X315 X319 X317 X400 X410	XXX08 XXX07 XXX09 Xxx	X351 X315 X319 X317 X410		X&xxxx;= 1 X&xxxx;= 1	X“
„607-230-00-6	2-xxxxxxxxxxxxx xxxxxxxx x&xxxx;xxxx soli, s výjimkou xxxx, které xxxx xxxxxxx jinde v této xxxxxxx	-	-	Xxxx. 1X	X360X	XXX08 Xxx	X360X“
„607-253-00-1	xxxxxxxxxx (XXX); [(3-xxxxxx-4-xxxxxxxxxx)xxxxxxxxxx]-3-(2,2-xxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx	269-855-7	68359-37-5	Xxxx. Xxxxx Xxx. 2 Xxxxx Xxx. 2 XXXX SE 1 Xxxxxxx Acute 1 Xxxxxxx Xxxxxxx 1	X362 X330 X300 X370 (xxxxxxx xxxxxx) X400 X410	XXX06 XXX08 XXX09 Xxx	X362 X330 X300 X370 (xxxxxxx xxxxxx) X410		xxxxxxxxx: XXX&xxxx;= 0,14&xxxx;xx/x (prach xxxx xxxx) xxxxxx: XXX&xxxx;= 14&xxxx;xx/xx TH M = 1&xxxx;000&xxxx;000 X&xxxx;= 1&xxxx;000&xxxx;000 “
„607-254-00-7	β-cyfluthrin (XXX); xxxxxxx xxxx: xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx x&xxxx;xxx-(X)-xxxx(4-xxxxx-3-xxxxxxxxxxx)xxxxxx-(1X,3X)-3-(2,2-xxxxxxxxxxxxxx)-2,2-xxxxxxxxxxxxxxxxxxx-1-xxxxxxxxxx	-	1820573-27-0	Xxxx. Xxxxx Tox. 2 Xxxxx Xxx. 2 XXXX XX 1 Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1	H362 H330 H300 H370 (xxxxxxx xxxxxx) X400 X410	XXX06 XXX08 XXX09 Xxx	X362 X330 X300 X370 (xxxxxxx xxxxxx) X410		xxxxxxxxx: XXX&xxxx;= 0,081&xxxx;xx/x (xxxxx xxxx xxxx) xxxxxx: XXX&xxxx;= 11&xxxx;xx/xx XX X&xxxx;= 1&xxxx;000&xxxx;000 X&xxxx;= 1 000 000 “
„607-734-00-6	xxxxxxxxxxx-2,2‘,2“,2“‘,2“&xxxx;“ -(xxxxx-1,2-xxxxxxxxxxx)xxxxxxxxxxx	404-290-3	7216-95-7	Xxxx. 1X Xxxxx Xxx. 4 XXXX RE 2 Xxx Irrit. 2	X360X X332 X373 (xxxxxxxxxx) X319	XXX08 XXX07 Xxx	X360X X332 X373 (xxxxxxxxxx) X319		Xxxx. 1B; X360X: X&xxxx;≥&xxxx;3&xxxx;% xxxxxxxxx: XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx nebo xxxx)“
„607-735-00-1	{[(xxxxxxxxxxxxx)xxxxx]xxx(xxxxxxxxxxxxxx)}xxxxxxxxxxx xxxxxxxx	200-652-8	67-43-6	Xxxx. 1B Acute Xxx. 4 XXXX XX 2 Xxx Xxxxx. 2	H360D H332 H373 (xxxxxxxxxx) X319	XXX08 XXX07 Xxx	X360X X332 X373 (xxxxxxxxxx) X319		Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;% xxxxxxxxx: XXX&xxxx;= 1,5 mg/l (xxxxx xxxx mlha)“
„607-736-00-7	pentanatrium-[(karboxylatomethyl)iminobis(ethylennitrilo)tetraacetát]	205-391-3	140-01-2	Repr. 1X Xxxxx Xxx. 4 XXXX XX 2	X360X X332 X373 (vdechování)	GHS08 GHS07 Dgr	H360D H332 H373 (xxxxxxxxxx)		Xxxx. 1X; H360D: X&xxxx;≥&xxxx;3&xxxx;% xxxxxxxxx: XXX&xxxx;= 1,5&xxxx;xx/x (xxxxx xxxx xxxx)“
„608-032-00-2	xxxxxxxxxxx (ISO); (1X)-X-[(6-xxxxxxxxxxxx-3-xx)xxxxxx]-X’-xxxx-X-xxxxxxxxxxxxxxxxxxx; (X)-X 1-[(6-chlor-3-pyridyl)methyl]-N 2-xxxx-X 1-xxxxxxxxxxxxxxxx	-	135410-20-7&xxxx;160430-64-8	Xxxx. 2 Xxxxx Xxx. 3 Xxxxxxx Xxxxxxx 1 Xxxxxxx Xxxxx 1	H361d H301 H410 H400	GHS08 GHS06 GHS09 Dgr	H361d H301 H410		orální: ATE = 140&xxxx;xx/xx XX X&xxxx;= 10 M = 10“
„609-042-00-X	xxxxxxxxxxxxx (XXX); X-(1-xxxxxxxxxxx)-2,6-xxxxxxx-3,4-xxxxxxx	254-938-2	40487-42-1	Xxxx. 2 Aquatic Xxxxx 1 Xxxxxxx Chronic 1	X361x X400 X410	XXX08 XXX09 Xxx	X361x X410		X&xxxx;= 100 X&xxxx;= 10“
„613-012-00-1	xxxxxxxx (XXX); 3-xxxxxxxxx-1X-2,1,3-xxxxxxxxxxxxxxx-4(3X)-xx-2,2-xxxxxx	246-585-8	25057-89-0	Xxxx. 2 Xxxxx Xxx. 4 Eye Xxxxx. 2 Xxxx Xxxx. 1	X361x X302 X319 X317	XXX08 XXX07 Xxx	X361x X302 X319 X317		xxxxxx: XXX&xxxx;= 1 600 mg/kg XX“
„616-164-00-7	xxxxxxxxxxxxx (ISO); (2E)-2-{2-[(2,5-dimethylfenoxy)methyl]fenyl}-2-(methoxyimino)-N-methylacetamid; (X)-2-(xxxxxxxxxxxx)-X-xxxxxx-2-[α-(2,5-xxxxxxxx)-x-xxxxx]xxxxxxxx		149961-52-4	Xxxx. 2 Xxxx. 2 Xxxxx Xxx. 4 Xxxxxxx Xxxxx 1 Xxxxxxx Xxxxxxx 1	H351 H361d H332 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H361d H332 H410		inhalační: ATE = 1,3&xxxx;xx/x (prach xxxx xxxx) X&xxxx;= 100 X&xxxx;= 100“

x)	xxxxxxx xxxxxxxxxxxx indexovému číslu 615-007-00-X se xxxxxxx.

Plné znění - 32022R0692

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

XXXXXXXX KOMISE V PŘENESENÉ XXXXXXXXX (XX) 2022/692

xx xxx 16. února 2022,

xxxxxx xx pro xxxxx xxxxxxxxxxxx vědeckotechnickému xxxxxxx xxxx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 x&xxxx;xxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx

Xxxxxx&xxxx;1

Xxxxxx&xxxx;2

Xxxxx x&xxxx;xxxxxxxx x&xxxx;xxxxxxxxxxxx

PŘÍLOHA

Plné znění - 32022R0692

Na co čekáte? Nečekejte už ani minutu. Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

XXXXXXXX KOMISE V PŘENESENÉ XXXXXXXXX (XX) 2022/692

xx xxx 16. února 2022,

xxxxxx xx pro xxxxx xxxxxxxxxxxx vědeckotechnickému xxxxxxx xxxx nařízení Xxxxxxxxxx xxxxxxxxxx x&xxxx;Xxxx (XX) x.&xxxx;1272/2008 x&xxxx;xxxxxxxxxxx, xxxxxxxxxx x&xxxx;xxxxxx xxxxx x&xxxx;xxxxx

Xxxxxx&xxxx;1

Xxxxxx&xxxx;2

Xxxxx x&xxxx;xxxxxxxx x&xxxx;xxxxxxxxxxxx

PŘÍLOHA

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.